how to evaluate peptide evidence
this cluster organizes one intent: deciding whether peptide claims are credible enough to act on.
1) verify study design before outcomes
give the strongest weight to randomized controlled human trials, then prospective cohorts, then retrospective reports, then animal or in vitro studies. peptide claims often invert this order.
- sample size, attrition, and randomization quality
- pre-registered endpoints vs post-hoc outcomes
- dose, route, and duration matching real use
2) measure effect size, not headline claims
large percentage headlines can hide small absolute effects. compare absolute change, confidence intervals, and clinically meaningful thresholds.
3) check reproducibility and conflicts
one positive paper is not enough. look for independent replication and evaluate sponsorship or commercial conflicts.
4) connect evidence to practical risk
evaluate adverse event rates, contraindications, and monitoring requirements before considering benefits.
next best pages
- GLP-1 comparisons cluster for real-world drug-class decision tradeoffs
- semaglutide course for a high-evidence peptide example
- BPC-157 course for a high-interest but low-human-data example
- GHK-Cu mastery for deep mechanistic interpretation
references
- Higgins JPT, et al. Cochrane Handbook for Systematic Reviews of Interventions.
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement.
- US FDA. Guidance on clinical trial endpoints and interpretation.
- Ioannidis JPA. Why most published research findings are false.